Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DOD Biotech PCLBKK:DOD-R -5.84%67 Days Sales Outstanding is 48.48 as of Jun. 2026, which is 14% below its 10-year median of 56.47. GuruFocus rates BKK:DOD-R with a GF Score™ of 67/100 and a GF Value™ of ฿1.52. The stock has 6 warning signs investors should review. Among 1,942 Consumer Packaged Goods companies, DOD Biotech PCL ranks better than 51.18% on this metric.
The historical rank and industry rank for DOD Biotech PCL's Days Sales Outstanding or its related term are showing as below:
BKK:DOD-R'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.07 Med: 56.47 Max: 120.42
Current: 38
During the past 12 years, DOD Biotech PCL's highest Days Sales Outstanding was 120.42. The lowest was 23.07. And the median was 56.47.
BKK:DOD-R's Days Sales Outstanding is ranked better than 51.18% of 1942
companies
in the Consumer Packaged Goods industry
Industry Median: 38.63
vs BKK:DOD-R: 38.00
DOD Biotech PCL's Days Sales Outstanding
increased
from Jun. 2025 (26.71) to Jun. 2026 (48.48).
DOD Biotech PCL (BKK:DOD-R) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
DOD Biotech PCL Days Sales Outstanding Related Terms
DOD Biotech PCL Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for DOD Biotech PCL's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:DOD-R vs KHC, GIS: Days Sales Outstanding Comparison
For the Packaged Foods subindustry, DOD Biotech PCL's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DOD Biotech PCL Days Sales Outstanding vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, DOD Biotech PCL's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where DOD Biotech PCL's Days Sales Outstanding falls into.
DOD Biotech PCL Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DOD Biotech PCL (BKK:DOD-R) has a Days Sales Outstanding of 48.48 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on DOD Biotech PCL and its competitors. This is 14% below median its historical median of 56.47. Over the past decade, DOD Biotech PCL's Days Sales Outstanding has ranged from 23.07 to 120.42. According to the industry distribution chart, DOD Biotech PCL ranks #948 out of 1942 companies in the Consumer Packaged Goods industry, placing it in the top 48.8%.
Is DOD Biotech PCL's Days Sales Outstanding too high?
DOD Biotech PCL's current Days Sales Outstanding of 48.48 is 14% below median its 10-year median of 56.47. Over the past 10 years, this metric has ranged from a low of 23.07 to a high of 120.42. The Consumer Packaged Goods industry median Days Sales Outstanding is 38.63. DOD Biotech PCL's value of 48.48 is 25.5% above this industry median. Based on the distribution chart, DOD Biotech PCL ranks #948 out of 1942 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, DOD Biotech PCL has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does DOD Biotech PCL's Days Sales Outstanding compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, DOD Biotech PCL ranks #948 out of 1942 companies for Days Sales Outstanding. This puts DOD Biotech PCL in the upper half of its industry. The industry median Days Sales Outstanding is 38.63. DOD Biotech PCL's value of 48.48 is 25.5% above this benchmark. Historically, DOD Biotech PCL's own Days Sales Outstanding has ranged from 23.07 to 120.42 over the past decade. While the company's 10-year median is 56.47 vs. the industry median of 38.63, DOD Biotech PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Consumer Packaged Goods company?
The median Days Sales Outstanding among Consumer Packaged Goods companies is 38.63, based on 1,942 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DOD Biotech PCL's current Days Sales Outstanding of 48.48 is 25.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on DOD Biotech PCL and its competitors. For the Consumer Packaged Goods industry, the median Days Sales Outstanding is 38.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DOD Biotech PCL's current Days Sales Outstanding is 48.48, which is 14% below median its own 10-year median of 56.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DOD Biotech PCL stock overvalued right now?
DOD Biotech PCL (BKK:DOD-R) has a current Days Sales Outstanding of 48.48. The stock's GF Value™ is ฿1.52, compared to a current price of ฿0.97 — trading 36.4% below its estimated fair value. The current Days Sales Outstanding is 48.48, which is 14% below median its 10-year median of 56.47 and 25.5% above the Consumer Packaged Goods industry median of 38.63. DOD Biotech PCL's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For DOD Biotech PCL (BKK:DOD-R), the current Days Sales Outstanding is 48.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DOD Biotech PCL (BKK:DOD-R) Overvalued in 2026?
Based on GuruFocus' analysis, DOD Biotech PCL stock appears to be undervalued.
The current stock price of ฿0.97 is trading 36.4% below its estimated GF Value™ of ฿1.52.
Key valuation signals for BKK:DOD-R:
Days Sales Outstanding: 48.48 (14% below median its 10-year median of 56.47)
GF Value™: ฿1.52 vs. price of ฿0.97 (36.4% below fair value)
Industry Position: 25.5% above the Consumer Packaged Goods median (#948 of 1942)
No single metric tells the full story. See the BKK:DOD-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The group is principally engaged in the supplement business. Its operations are carried on only in Thailand. Its products include: Capsule; Gel; Jelly; Powder for making drinks; Concentrated water extract (Shot Drink); Softgel; Tablet; Probiotics; Gummies; and Direct-to-Mouth Packaging.
67GF Score
Get the complete analysis for BKK:DOD-R
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:DOD-R has been successfully added to your 
